Georgina K. Fensom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Georgina K. Fensom has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Timothy J. Key
Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK
20 shared publications - Ruth C. Travis
Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
19 shared publications - Eleanor L. Watts
Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD
17 shared publications - Aurora Perez-Cornago
European Commission, Joint Research Centre (JRC), Ispra, Italy
11 shared publications - Elio Riboli
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
11 shared publications - Konstantinos K. Tsilidis
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
11 shared publications
Latest Publications
- 1 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , 1222-1223
Evaluation of the 4Kscore in EPIC: Reply
- 1 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , 1222-1223
Evaluation of the 4Kscore in EPIC: Reply
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4K score models with prostate cancer overall and clinically relevant disease subtypes and among men with elevated PSA stratified by EPIC recruitment country
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4K score models with prostate cancer overall and clinically relevant disease subtypes and among men with elevated PSA stratified by EPIC recruitment country
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Correlations between analytes and 4Kscore.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Correlations between analytes and 4Kscore.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table 4 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4Kscore models with prostate cancer overall and clinically relevant disease subtypes and among men with elevated PSA who developed cancer.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4Kscore models with prostate cancer overall and clinically relevant disease subtypes and among men with elevated PSA who developed cancer.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Characteristics of control participants and patients with prostate cancer.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Characteristics of control participants and patients with prostate cancer.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4K score models with prostate cancer overall and clinically relevant disease subtypes and among men with elevated PSA developed cancer within five years of recruitment and more than five years after recruitment
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4K score models with prostate cancer overall and clinically relevant disease subtypes and among men with elevated PSA developed cancer within five years of recruitment and more than five years after recruitment
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Adjusted geometric mean PSA concentration (ng/mL) and 4Kscore in controls by selected characteristics.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Adjusted geometric mean PSA concentration (ng/mL) and 4Kscore in controls by selected characteristics.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4K score models with prostate cancer overall and clinically relevant disease subtypes and among men with elevated PSA who were under the age of 60 at recruitment and over the age of 60 at recruitment
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4K score models with prostate cancer overall and clinically relevant disease subtypes and among men with elevated PSA who were under the age of 60 at recruitment and over the age of 60 at recruitment
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4K score models with prostate cancer overall and clinically relevant disease subtypes stratified by EPIC recruitment centre
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
AUC results for PSA and the 4K score models with prostate cancer overall and clinically relevant disease subtypes stratified by EPIC recruitment centre
- Open Access
- 22 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2058-2067
Evaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Background: PSA is central to referrals for prostate biopsy but has low specificity for aggressive prostate cancer. This study evaluates the 4Kscore (OPKO Diagnostics) versus total PSA in predicting short- and long-term risks of aggressive prostate cancer. Methods: Baseline blood samples from 1,658 men diagnosed with prostate cancer (median diagnosis time = 8.6 years) and 1,658 matched controls in the European Prospective Investigation into Cancer and Nutrition were analyzed. Discrimination for the 4Kscore and total PSA was assessed using the AUC with 95% confidence intervals (CI) via bootstrapping. Results: For high-grade tumors, AUCs were 0.69 (95% CI, 0.66–0.72) for the 4Kscore and 0.75 (95% CI, 0.73–0.78) for total PSA. For advanced-stage disease, AUCs were 0.71 (95% CI, 0.66–0.75) for the 4Kscore and 0.77 (95% CI, 0.73–0.80) for total PSA. Similar findings were observed for other aggressive cancer endpoints. Among men with PSA >2 ng/mL, the 4Kscore had better discrimination than PSA for overall prostate cancer, high-grade disease, and prostate cancer death but only in men <60 years at recruitment. Conclusions: In this large European study, the 4Kscore did not significantly improve the prediction of clinically significant prostate cancer compared with total PSA, except in younger men with elevated PSA. Impact: The findings underscore the limited utility of the 4Kscore in improving medium- to longer-term risk prediction over PSA, with potential benefits restricted to younger men with elevated PSA.
- 22 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2058-2067
Open AccessEvaluation of the 4Kscore Test in Relation to Subsequent Risk of Aggressive Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition
Background: PSA is central to referrals for prostate biopsy but has low specificity for aggressive prostate cancer. This study evaluates the 4Kscore (OPKO Diagnostics) versus total PSA in predicting short- and long-term risks of aggressive prostate cancer. Methods: Baseline blood samples from 1,658 men diagnosed with prostate cancer (median diagnosis time = 8.6 years) and 1,658 matched controls in the European Prospective Investigation into Cancer and Nutrition were analyzed. Discrimination for the 4Kscore and total PSA was assessed using the AUC with 95% confidence intervals (CI) via bootstrapping. Results: For high-grade tumors, AUCs were 0.69 (95% CI, 0.66–0.72) for the 4Kscore and 0.75 (95% CI, 0.73–0.78) for total PSA. For advanced-stage disease, AUCs were 0.71 (95% CI, 0.66–0.75) for the 4Kscore and 0.77 (95% CI, 0.73–0.80) for total PSA. Similar findings were observed for other aggressive cancer endpoints. Among men with PSA >2 ng/mL, the 4Kscore had better discrimination than PSA for overall prostate cancer, high-grade disease, and prostate cancer death but only in men <60 years at recruitment. Conclusions: In this large European study, the 4Kscore did not significantly improve the prediction of clinically significant prostate cancer compared with total PSA, except in younger men with elevated PSA. Impact: The findings underscore the limited utility of the 4Kscore in improving medium- to longer-term risk prediction over PSA, with potential benefits restricted to younger men with elevated PSA.